PuraPharm Corporation Limited announced consolidated earnings results for the year ended December 31, 2016. For the full year, the company reported Revenue was HKD 535,986,000 against revenue of HKD 473,900,000 a year ago. Profit before tax was HKD 38,667,000 against profit before tax of HKD 40,134,000 a year ago. Profit for the year was HKD 32,162,000 against profit for the year of HKD 28,458,000 a year ago. Profit attributable to owners of the parent was HKD 32,162,000 against profit attributable to owners of the parent of HKD 28,458,000 a year ago. Basic and diluted earnings per share were HKD 0.14 against basic and diluted earnings per share of HKD 0.15 a year ago. Net cash used in operating activities was HKD 55,828,000 against net cash used in operating activities of HKD 12,570,000 a year ago. For the year ended 31 December 2016, the Group's net cash used in investing activities was HKD 65.2 million, which was primarily attributable to the capital expenditures incurred for acquisition of production equipment and enhancement of existing production line, establishment of new Nong's Chinese medicine clinics and acquisition of intellectual properties in respect of the two Chinese medicines management software for clinic operation.